Amylyx Pharmaceuticals, Inc. AMLX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Excluding Acquired In Process Cost by Product | ||||||
| AMX0035PSP | $649K-85.8% | $2.56M-39.8% | $3M-39.3% | $7.15M+102% | $4.56M+9.0% | |
| Avexitide | $9.99M+84.1% | $6.68M+151% | $4.89M+4,424% | $7.11M— | $5.43M— | |
| Other Programs | $7.98M+111% | $4.09M— | $3.65M-10.6% | $3.97M+78.5% | $3.77M+47.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amylyx Pharmaceuticals, Inc. break its business down?
- Amylyx Pharmaceuticals, Inc. (AMLX) reports research and development expense excluding acquired in process cost by product across 3 parts — AMX0035PSP, Avexitide and Other Programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Amylyx Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amylyx Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.